Merkel Cell Carcinoma (MCC)

01The AEIOU mnemonic (Heath 2008) captures the clinical phenotype with sensitivity above 89%: Asymptomatic (88%), Expanding rapidly within 3 months (63%), Immunosuppressed (8% of cases but 24-fold relative risk), Older than 50 years (90%), and located on UV-exposed skin (81%). Three or more features were present in 89% of cases. The lesion is most often a firm, painless, red to violaceous dome-shaped papule or nodule on the head, neck, or extremity, frequently mistaken clinically for a cyst, lipoma, or pyogenic granuloma.

02Dermoscopy of MCC has no pathognomonic pattern. The most reproducibly described features are a milky-red to pinkish-violet structureless background, polymorphic (atypical) vessels including linear-irregular, dotted, glomerular, hairpin, serpentine, and arborizing morphologies often distributed irregularly, and ulceration. Pigmented structures and pigment network are absent. The dermoscopic differential overlaps with amelanotic melanoma, BCC, atypical fibroxanthoma, cutaneous lymphoma, and metastases. Because the picture is nonspecific, a rapidly growing red nodule on sun-damaged skin in an older patient is a biopsy lesion regardless of dermoscopic appearance.

03MCPyV was discovered by Feng and colleagues in 2008 (Science 319:1096) using digital transcriptome subtraction. Two viral T-antigen oncoproteins (large T and small T) are expressed in tumor cells; the large T antigen retains Rb-binding activity but loses helicase function due to truncating mutations, locking infected cells in a proliferative state. MCPyV-positive tumors typically arise on the trunk and extremities of immunocompromised hosts and have a relatively low mutation burden. MCPyV-negative tumors arise on the head, neck, and dorsal hands of fair-skinned older patients, show a UV-signature mutation burden among the highest of any human cancer, and respond similarly well to immunotherapy.

04Pathology shows small round blue cells with scant cytoplasm, salt-and-pepper chromatin, and brisk mitoses arranged in trabecular, nodular, or diffuse architecture. Immunohistochemistry is essential: cytokeratin 20 (CK20) shows a paranuclear dot-like pattern in roughly 90% of tumors, and neuroendocrine markers (synaptophysin, chromogranin, INSM1) are positive. TTF-1 negativity excludes metastatic small-cell lung carcinoma. CK20-negative MCC variants exist and require correlation with neuroendocrine markers and clinical context.

05Staging follows AJCC 8th edition. Sentinel lymph node biopsy is recommended for all clinically node-negative primaries because nodal involvement is occult in roughly one-third and upstages 25 to 30% of patients. PET-CT or whole-body CT is used for tumors with palpable nodes, primary larger than 1 cm, or any high-risk feature. Baseline serology for the MCPyV oncoprotein antibody (AMERK assay) is increasingly used: rising titers in initially seropositive patients precede clinical recurrence by months and inform surveillance.

06Surgical management is wide local excision with 1 to 2 cm margins to deep fascia where feasible, with Mohs micrographic surgery preferred at functionally sensitive sites. Adjuvant radiotherapy to the primary site reduces local recurrence by approximately 50% in retrospective series and is standard of care unless contraindicated. Nodal radiation or completion lymphadenectomy is offered after positive SLNB.

07Immune checkpoint inhibitors transformed metastatic MCC management. Avelumab (anti-PD-L1) received accelerated FDA approval in 2017 for metastatic MCC based on the JAVELIN Merkel 200 trial, with response rates around 33% and durable disease control. Pembrolizumab (anti-PD-1) showed a 56% response rate as first-line therapy for metastatic disease (CITN-09 / KEYNOTE-017) and is FDA approved for adult and pediatric advanced MCC. Both MCPyV-positive and MCPyV-negative tumors respond, the former because of viral antigens and the latter because of UV-driven neoantigens. Adjuvant checkpoint inhibition after resection of high-risk disease is being studied (ADAM, ADMEC-O trials).

08Presentation in skin of color is underdiagnosed because clinicians often dismiss a small red papule on dark skin as benign, and atlas images underrepresent darker phototypes. In Hispanic and Black patients MCC tends to present at later stage and on more cosmetically apparent sites; suspicion thresholds should be lower for any rapidly growing pink-to-violaceous nodule regardless of skin tone.